Unlike broad chemotherapeutics, MEAP exploits this cancer-specific centrosome amplification by paradoxically hyperactivating them via NEDD9-STAT3 disruption, forcing multipolar mitosis and ALDH+ elimination while sparing bulk tumor cells. This evidence concerns the gene NEDD9 and neoplasm.